Stock listing
ADCT Stock Price, News, Filings & Events — Adc Therapeutics Sa
Selected listing: ADCT · NYSE · USD · US
This page tracks Adc Therapeutics Sa's ADCT:NYSE listing on NYSE in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following ADCT:NYSE. ADCT:NYSE is the stock-level entry point for investors researching Adc Therapeutics Sa, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Adc Therapeutics SA is a public company traded under the ticker ADCT in the American market. The company has a market capitalization of approximately $171.7 million. Adc Therapeutics focuses on developing targeted therapies for patients with hematologic malignancies and solid tumors.
- Ticker
- ADCT:NYSE
- Asset type
- Stock
- Market cap
- $127.2M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- NYSE
- Currency
- USD
Adc Therapeutics Sa ADCT:NYSE stock context
This page tracks Adc Therapeutics Sa's ADCT:NYSE listing on NYSE in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following ADCT:NYSE. ADCT:NYSE is the stock-level entry point for investors researching Adc Therapeutics Sa, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Adc Therapeutics SA is a public company traded under the ticker ADCT in the American market. The company has a market capitalization of approximately $171.7 million. Adc Therapeutics focuses on developing targeted therapies for patients with hematologic malignancies and solid tumors.
Latest news from Adc Therapeutics Sa
ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
August 13, 2026
ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
June 30, 2026
ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities
June 24, 2026
ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapse...
June 3, 2026
ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates
May 4, 2026
Adc Therapeutics Sa earnings calls
ADC Therapeutics SA (ADCT) Q2 2026 Earnings Call
August 13, 2026 · Replay with transcript and chapters
ADC Therapeutics SA (ADCT) Q1 2026 Earnings Call
May 4, 2026 · Replay with transcript and chapters
ADC Therapeutics SA (ADCT) Q4 2025 Earnings Call
March 10, 2026 · Replay with transcript and chapters
ADC Therapeutics SA (ADCT) Q3 2025 Earnings Call
November 10, 2025 · Replay with transcript and chapters
ADC Therapeutics SA (ADCT) Q2 2025 Earnings Call
August 12, 2025 · Replay with transcript and chapters
ADC Therapeutics SA (ADCT) Q1 2025 Earnings Call
May 14, 2025 · Replay with transcript and chapters
Research Adc Therapeutics Sa
Adc Therapeutics Sa investor report
Review AI stock analysis and investor report context for ADCT:NYSE.
Adc Therapeutics Sa company profile
View the public company page for Adc Therapeutics Sa on 6ix.
Adc Therapeutics Sa news
Read company news and market updates connected to Adc Therapeutics Sa.
Adc Therapeutics Sa investor events
Find investor webinars, events, and replay context for Adc Therapeutics Sa.